Bile duct cancer (cholangiocarcinoma) is one of the more aggressive cancers, with an overall 5-year survival rate in the single digits for advanced disease and a median survival of just 4 months without treatment. Most cases are diagnosed late, recurrence after surgery is common, and only a small fraction of patients are candidates for the operation that offers the best chance of long-term survival.
Why It’s Usually Found Late
The bile ducts are small tubes buried deep inside and around the liver, which means tumors can grow for months without producing noticeable symptoms. Early bile duct cancers rarely cause pain. The most common first sign is jaundice, a yellowing of the skin and whites of the eyes caused by a blocked bile duct trapping a waste pigment called bilirubin in the blood. Most people also develop intense itching from that same buildup, and some notice dark urine, pale stools, or unexplained weight loss.
The problem is that these symptoms only appear once the tumor is large enough to physically obstruct bile flow. By that point, the cancer has often spread into surrounding tissue or lymph nodes. Roughly two-thirds of patients already have stage III or IV disease at diagnosis.
Survival Rates by Stage and Location
Bile duct cancer behaves differently depending on where it starts. The two main types are intrahepatic (inside the liver) and extrahepatic (outside the liver, closer to the small intestine). Based on cases diagnosed between 2015 and 2021, here’s what the 5-year survival numbers look like:
For intrahepatic bile duct cancer: 25% when the tumor is still confined to its original site, 12% when it has spread to nearby tissue or lymph nodes, and 3% when it has reached distant organs. For extrahepatic bile duct cancer: 19% for localized disease, 20% for regional spread, and 2% for distant metastasis.
Extrahepatic tumors actually carry a higher 90-day mortality rate (11.4% vs. 8.2%), and patients with this type are about 21% less likely to survive overall compared to those with intrahepatic disease. That said, intrahepatic tumors tend to grow larger before detection. Over 62% of intrahepatic tumors exceed 5 centimeters at diagnosis, compared to about 21% of extrahepatic tumors. Intrahepatic cancers also spread to bone and lungs more frequently.
How Fast It Grows and Spreads
Researchers measure tumor aggressiveness partly through “doubling time,” the number of days it takes a tumor to double in volume. For the mass-forming type of intrahepatic bile duct cancer, a doubling time under 70 days is associated with significantly worse survival. Tumors that double that quickly tend to outpace treatment, even after surgical removal.
Bile duct cancer spreads primarily within the abdomen. Distant metastasis to organs like the brain or bones is less common than with some other cancers, but the disease readily invades the liver itself, nearby lymph nodes, and the lining of the abdominal cavity (the peritoneum). This local aggressiveness is a defining feature: the cancer tends to infiltrate surrounding structures rather than scattering widely to distant sites, which makes complete surgical removal difficult.
Surgery Is Possible for Very Few Patients
Complete surgical removal of the tumor remains the only realistic path to long-term survival. But only a small percentage of patients have tumors that are considered resectable, meaning the cancer hasn’t grown into critical blood vessels or spread too far for a surgeon to clear it entirely.
Even among those who do undergo successful surgery, about half will see their cancer return. A study of 193 patients who had complete resections found that 49% experienced recurrence, with a median time to recurrence of just over 15 months. Most recurrences happen within the liver and bile duct system rather than at distant sites. This high recurrence rate is a major reason bile duct cancer is considered so aggressive: even the best-case surgical scenario carries a coin-flip chance of the cancer coming back within a year or two.
What Treatment Adds to Survival
The difference between receiving treatment and not receiving it is stark. A large database analysis found that patients who underwent surgery had a median survival of 26 months, compared to 4 months for those who did not. Chemotherapy extended median survival to 12 months versus 3 months without it. Radiation therapy showed a median survival of 15 months compared to 5 months without.
For advanced cases where surgery isn’t possible, the current standard treatment combines chemotherapy with an immunotherapy drug that helps the immune system recognize and attack cancer cells. These regimens have been shown to extend survival beyond what chemotherapy alone achieves, though they are not curative for most patients. Only about 22% of all bile duct cancer patients undergo surgery, and roughly 43% receive chemotherapy.
What Makes It More or Less Aggressive
Several factors influence how a specific case is likely to behave. Tumor location matters: extrahepatic cancers are diagnosed slightly earlier on average but carry worse short-term survival, while intrahepatic cancers are more likely to metastasize to the lungs and bones. Tumor growth rate is another key variable. Cancers with a doubling time under 70 days behave far more aggressively than slower-growing tumors, even at the same stage.
Advanced stage at diagnosis is the single strongest predictor of poor outcomes. Because there is no routine screening test for bile duct cancer, and because symptoms appear late, most patients start treatment at a disadvantage. The cancers that are caught early, often incidentally during imaging for another condition, have the best prognosis. A localized intrahepatic tumor still carries a 1-in-4 chance of 5-year survival, which, while sobering, is dramatically better than the 2 to 3% survival rate once the disease has spread to distant organs.